核苷单磷酸前药作为抗丙型肝炎病毒药物的研究进展。
Advances in nucleoside monophosphate prodrugs as anti-HCV agents.
作者信息
Bobeck Drew R, Schinazi Raymond F, Coats Steven J
机构信息
RFS Pharma LLC, Tucker, GA, USA.
出版信息
Antivir Ther. 2010;15(7):935-50. doi: 10.3851/IMP1667.
Abstract
Nucleoside monophosphate prodrugs that are eventually bioconverted to the active nucleoside triphosphate (NTP) offer the potential to deliver increased intracellular NTP levels and/or organ-specific NTP enhancement. There are several classes of monophosphate prodrugs that have been applied to HCV drug discovery, and some of these approaches are currently being evaluated in humans. This review discusses recent advances in monophosphate prodrug approaches to improve oral absorption, stability and pharmacokinetic profile, including their advantages and potential pitfalls.
摘要
最终生物转化为活性核苷三磷酸（NTP）的核苷单磷酸前药，具有提高细胞内NTP水平和/或器官特异性NTP增强的潜力。有几类单磷酸前药已应用于丙型肝炎病毒（HCV）药物研发，其中一些方法目前正在人体中进行评估。本综述讨论了单磷酸前药方法在改善口服吸收、稳定性和药代动力学方面的最新进展，包括其优点和潜在问题。
相似文献
1
Advances in nucleoside monophosphate prodrugs as anti-HCV agents.核苷单磷酸前药作为抗丙型肝炎病毒药物的研究进展。
Antivir Ther. 2010;15(7):935-50. doi: 10.3851/IMP1667.
2
Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk.重组人线粒体RNA聚合酶介导的抗病毒核苷酸掺入可预测体内线粒体毒性风险增加。
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7077-7085. doi: 10.1128/AAC.01253-16. Print 2016 Dec.
3
Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.用于改善口服吸收和组织靶向性的核苷类似物前药。
J Pharm Sci. 2008 Mar;97(3):1109-34. doi: 10.1002/jps.21047.
4
Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors.前药策略提高核苷类抗病毒抑制剂的疗效。
Curr Opin HIV AIDS. 2013 Nov;8(6):556-64. doi: 10.1097/COH.0000000000000007.
5
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability.核苷前药R1626的物理化学性质导致其具有高口服生物利用度。
Drug Dev Ind Pharm. 2008 Jul;34(7):683-91. doi: 10.1080/03639040701836636.
6
2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938.2'-脱氧-2'-α-氟-2'-β-C-甲基 3',5'-环磷酸核苷酸前药类似物作为 HCV NS5B 聚合酶抑制剂的研究：PSI-352938 的发现。
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7376-80. doi: 10.1016/j.bmcl.2010.10.035. Epub 2010 Oct 15.
7
Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.新型β-D-2'-C-甲基-4'-叠氮嘧啶核苷亚磷酰胺前药的抗丙型肝炎病毒活性
Antivir Chem Chemother. 2009 Oct 19;20(2):99-106. doi: 10.3851/IMP1400.
8
Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.环状磷酰胺酯作为2'-C-甲基胞苷的前药
Eur J Med Chem. 2009 Sep;44(9):3765-70. doi: 10.1016/j.ejmech.2009.04.043. Epub 2009 May 8.
9
Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees.在感染丙型肝炎病毒的黑猩猩中给予 HepDirect 2'-C-甲基胞苷前药后的抗病毒疗效。
Antimicrob Agents Chemother. 2011 Aug;55(8):3854-60. doi: 10.1128/AAC.01152-10. Epub 2011 May 31.
10
Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection.用于治疗丙型肝炎病毒感染的2'-C-甲基腺苷肝靶向前药
J Med Chem. 2007 Aug 9;50(16):3891-6. doi: 10.1021/jm0701021. Epub 2007 Jul 18.
引用本文的文献
1
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.在健康志愿者和丙型肝炎病毒感染受试者中的安全性、耐受性和药代动力学的 AL-335。
PLoS One. 2018 Oct 16;13(10):e0204974. doi: 10.1371/journal.pone.0204974. eCollection 2018.
2
Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection.核苷酸前药在丙型肝炎病毒感染治疗中的当前及未来应用。
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618756430. doi: 10.1177/2040206618756430.
3
Synthesis and Anti-HCV Activity of a Novel 2',3'-Dideoxy-2'-α-fluoro-2'-β--methyl Guanosine Phosphoramidate Prodrug.新型2',3'-二脱氧-2'-α-氟-2'-β-甲基鸟苷磷酰胺酯前药的合成及其抗丙型肝炎病毒活性
ACS Med Chem Lett. 2017 May 1;8(6):682-684. doi: 10.1021/acsmedchemlett.7b00174. eCollection 2017 Jun 8.
4
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.β-D-2'-C-甲基-2,6-二氨基嘌呤核糖核苷亚磷酰胺是丙型肝炎病毒（HCV）的强效和选择性抑制剂，并在细胞内生物转化为具有生物活性的2,6-二氨基嘌呤和5'-三磷酸鸟苷形式。
J Med Chem. 2015 Apr 23;58(8):3445-58. doi: 10.1021/jm501874e. Epub 2015 Apr 7.
5
Prodrugs of phosphonates and phosphates: crossing the membrane barrier.膦酸盐和磷酸盐的前药：跨越膜屏障
Top Curr Chem. 2015;360:115-60. doi: 10.1007/128_2014_561.
6
Synthesis of nucleoside phosphate and phosphonate prodrugs.核苷磷酸酯和膦酸酯前药的合成。
Chem Rev. 2014 Sep 24;114(18):9154-218. doi: 10.1021/cr5002035. Epub 2014 Aug 21.
7
Chutes and ladders in hepatitis C nucleoside drug development.丙型肝炎核苷类药物研发中的陷阱与出路。
Antiviral Res. 2014 Feb;102:119-47. doi: 10.1016/j.antiviral.2013.11.008. Epub 2013 Nov 23.
8
Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design.α-P-硼烷磷酸核苷酸抑制丙型肝炎病毒 RNA 依赖的 RNA 聚合酶：探索基于机制的丙型肝炎病毒药物设计的潜在策略。
Antiviral Res. 2013 May;98(2):144-52. doi: 10.1016/j.antiviral.2013.02.014. Epub 2013 Mar 4.
9
Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection.利用苄氧羰基保护高效合成核苷芳氧基磷酰胺酯前药
Tetrahedron. 2011 Jul 29;67(30):5487-5493. doi: 10.1016/j.tet.2011.05.046.
10
Antiviral activity of nucleoside analogues against norovirus.核苷类似物对诺如病毒的抗病毒活性。
Antivir Ther. 2012;17(6):981-91. doi: 10.3851/IMP2229. Epub 2012 Aug 14.
本文引用的文献
1
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures.微尺度原代人肝细胞培养物中持续性丙型肝炎病毒感染。
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3141-5. doi: 10.1073/pnas.0915130107. Epub 2010 Feb 1.
2
HCV drug discovery aimed at viral eradication.HCV 药物研发旨在实现病毒清除。
J Viral Hepat. 2010 Feb 1;17(2):77-90. doi: 10.1111/j.1365-2893.2009.01246.x. Epub 2009 Dec 18.
3
Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.新型β-D-2'-C-甲基-4'-叠氮嘧啶核苷亚磷酰胺前药的抗丙型肝炎病毒活性
Antivir Chem Chemother. 2009 Oct 19;20(2):99-106. doi: 10.3851/IMP1400.
4
Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.用于治疗丙型肝炎病毒感染的2'-C-甲基胞苷的磷酰胺酯前药。
J Med Chem. 2009 Sep 10;52(17):5394-407. doi: 10.1021/jm900447q.
5
HCV NS5B polymerase inhibitors.丙型肝炎病毒NS5B聚合酶抑制剂
Clin Liver Dis. 2009 Aug;13(3):453-65. doi: 10.1016/j.cld.2009.05.001.
6
The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.磷酰胺酯前药方法极大地增强了β-2'-C-甲基鸟苷对丙型肝炎病毒的活性。
Bioorg Med Chem Lett. 2009 Aug 1;19(15):4316-20. doi: 10.1016/j.bmcl.2009.05.122. Epub 2009 Jun 10.
7
Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.环状磷酰胺酯作为2'-C-甲基胞苷的前药
Eur J Med Chem. 2009 Sep;44(9):3765-70. doi: 10.1016/j.ejmech.2009.04.043. Epub 2009 May 8.
8
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.9-(S)-(3-羟基-2-膦酰甲氧基丙基)腺嘌呤的烷氧基烷基酯在体外以及在体内的乙肝病毒转基因小鼠中都是乙肝病毒（HBV）复制的强效且选择性抑制剂。
Antimicrob Agents Chemother. 2009 Jul;53(7):2865-70. doi: 10.1128/AAC.00114-09. Epub 2009 Apr 27.
9
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.（S）-9-[3-羟基-2-（膦酰甲氧基）丙基]腺嘌呤的十八烷氧基乙酯是1A、1B和2A基因型复制子中丙型肝炎病毒复制的有效且选择性抑制剂。
Antimicrob Agents Chemother. 2009 Jun;53(6):2660-2. doi: 10.1128/AAC.01546-08. Epub 2009 Mar 16.
10
Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase.2'-甲基胞苷新型磷酰胺酯前药作为丙型肝炎病毒NS5B聚合酶抑制剂的合成与评价
Bioorg Med Chem Lett. 2009 Mar 1;19(5):1392-5. doi: 10.1016/j.bmcl.2009.01.035. Epub 2009 Jan 19.
Zotero 插件